# OraLiva

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oraliva

- Industry: Healthcare
- Headquarters: New York, US
- Website: www.oraliva.com/
- Total disclosed funding: $2M
- Latest round: Seed (Oct 7, 2025)
- Investors on record: 3

## About

OraLiva, Inc. is a US-based company focused on non-invasive oral cancer screening, leveraging proprietary technology to improve detection and diagnosis of oral cancer through AI-powered analysis.Founded in 2019 and headquartered in New York, US, OraLiva, Inc. specializes in oral cancer diagnostics. The company has successfully completed 1 funding round, raising a total of USD 2.00 mn in Seed funding, led by Data Collective, NYU Venture Capital, and RTP Angel Fund. The most recent deal was finalized on October 7, 2025.OraLiva specializes in non-invasive oral cancer screening through its proprietary brush biopsy technology, which employs AI-powered cytology to deliver rapid, accurate insights into potential oral cancer and dysplasia. The core product is the OraLiva brush biopsy device, designed to collect transepithelial cell samples from suspicious lesions during routine dental examinations without the need for scalpels or anesthesia. This process is streamlined for dental providers, enabling sample collection in just minutes and producing results within days, facilitating timely patient counseling or specialist referrals. The primary clientele includes general dentists, dental support organizations (DSOs), and oral health specialists across various geographical markets, including the United States and potentially expanding into international markets, where there is a demand for advanced oral cancer detection tools.OraLiva generates revenue through direct sales of its brush biopsy devices and associated AI-powered analysis services to dental practices. The transaction structure primarily follows a B2B model, where dental practices purchase the devices and may engage in ongoing usage fees for the AI analysis and reporting services provided. This business model is designed to enhance clinical workflows by integrating OraLiva’s technology into routine dental examinations, thereby improving patient outcomes and generating additional revenue for dental providers. Although specific pricing details for the devices and services are not disclosed, the offerings are aimed at providing a cost-effective solution for oral cancer detection, bolstering both practice revenue and patient care efficacy.In October 2025, OraLiva, Inc. raised USD 2.00 mn in Seed funding, which will be allocated for the commercial launch setup of their oral cancer test and the establishment of a laboratory in Durham, North Carolina. The company plans to advance regulatory pathways for point-of-care device clearance and is exploring diagnostic model transfer learning for bladder cancer, anal cancer, and cervical cancer. Additionally, OraLiva aims to expand its market presence, targeting not only the United States but also international regions in need of innovative oral cancer detection solutions.

## Funding rounds

- Seed, Oct 7, 2025, $2M — NYU Venture Capital, DCVC, RTP Angel Fund

## Investors

- NYU Venture Capital (https://capitalatlas.ai/funds/nyu-venture-capital) — Seed
- DCVC (https://capitalatlas.ai/funds/dcvc) — Seed
- RTP Angel Fund (https://capitalatlas.ai/funds/rtp-angel-fund) — Seed